Setara Biosciences Raises $90 Million Series A To Advance Rare Disease Precision Medicines

Setara Biosciences has raised $90 million in Series A financing to advance a pipeline of precision medicines targeting rare genetic diseases and potentially broader indications.

The company was created following Jazz Pharmaceuticals’ acquisition of Actio Biosciences for Actio’s lead program, ABS-1230, which is being developed for KCNT1-related epilepsy.

Setara will continue developing the remaining Actio pipeline.

Investors in the Series A include Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures, and Jazz Pharmaceuticals.

Setara’s lead program is STAR-0871, formerly known as ABS-0871.

The investigational oral small-molecule drug inhibits TRPV4 and is being developed initially for Charcot-Marie-Tooth disease type 2C and overactive bladder.

CMT2C is a rare inherited neuromuscular disorder caused by gain-of-function mutations in the TRPV4 gene.

Setara estimates the condition affects approximately 2,500 people in the U.S.

The company said STAR-0871 is designed to selectively inhibit TRPV4 and directly address the underlying biological cause of CMT2C.

Setara has completed the healthy volunteer portion of a Phase 1 clinical trial.

The company plans to begin a Phase 1b study called THERON in patients with CMT2C during 2027.

STAR-0871 has received Rare Pediatric Disease, Orphan Drug, and Fast Track designations from the U.S. Food and Drug Administration.

Setara also intends to begin a Phase 2a study of the drug in patients with overactive bladder, a condition affecting tens of millions of people in the U.S.

Beyond STAR-0871, the company is developing early-stage programs targeting genetic epilepsies and broader indications including migraine.

Setara is led by Actio co-founder David Goldstein, who will serve as president and executive chair.

KEY QUOTES:

“Setara allows us to take the next step in our journey, to carry forward a pipeline of promising programs for rare diseases, with the potential to ultimately reach much broader patient populations.”

David Goldstein, Ph.D., Co-Founder, President And Executive Chair Of Setara Biosciences

“Setara brings together experienced operators, a compelling foundation in human genetics, and a promising pipeline grounded in strong biological rationale.”

Jason Fuller, Ph.D., Board Member Of Setara Biosciences And Partner At Deerfield Management